

Biologics CDMO Market Size, Share And Growth Analysis For 2024-2033

*The Business Research Company's
Biologics CDMO Global Market Report
2024 – Market Size, Trends, And Forecast
2024-2033*

LONDON, GREATER LONDON, UK, June 21, 2024 /EINPresswire.com/ -- The biologics CDMO market is poised for remarkable growth, with its market size expected to increase from \$18.44

billion in 2023 to \$21.30 billion in 2024, reflecting a compound annual growth rate (CAGR) of 15.4%. The market is forecasted to reach \$36.54 billion by 2028 at a CAGR of 14.4%. This expansion is driven by the rising demand for biologic therapies, the emergence of biosimilars and biobetters, investments in biomanufacturing infrastructure, and a shift towards outsourcing complex processes.



You Can Now Pre Order
Your Report To Get A Swift
Deliver With All Your Needs
"

*The Business Research
Company*

Surge in Demand for Cell and Genetic Therapy Fuels
Market Growth

The increasing demand for cell and genetic therapy is a major driver of the biologics CDMO market. These therapies offer innovative treatments by addressing diseases at the cellular or genetic level, providing potential solutions for conditions that are challenging to manage

with traditional pharmaceuticals. Biologics CDMOs play a crucial role in this sector by providing expertise in handling living cells, viral vectors, and genetic material, ensuring safe and efficient production. According to the American Society of Gene & Cell Therapy (ASGCT), the gene, cell, and RNA therapy pipeline grew by 7% in 2022, with a total of 3,726 therapies in development. This surge underscores the growing reliance on biologics CDMOs for advancing these groundbreaking therapies.

Explore comprehensive insights into the global biologics CDMO market with a detailed sample report: https://www.thebusinessresearchcompany.com/sample_request?id=14056&type=smp

Key Players and Market Trends

The Business
Research Company

Biologics CDMO Market Report 2024 – Market Size,
Trends, And Forecast 2024-2033



Leading companies in the biologics CDMO market include AbbVie Inc., Thermo Fisher Scientific Inc., and Novartis AG. These companies focus on developing advanced solutions to enhance biopharmaceutical development and manufacturing. For instance, Lonza Group's launch of GS Effex cell lines in November 2023 represents a significant technological advancement, producing therapeutic antibodies with increased potency and addressing immunotherapy challenges.

Major Trends in the Biologics CDMO Market

The forecast period will see significant trends such as the expansion of capabilities to offer end-to-end solutions, the adoption of single-use technologies, and the integration of continuous manufacturing processes. Additionally, the emergence of specialized CDMOs is expected to shape the market landscape. These trends highlight the industry's commitment to improving efficiency and meeting the complex demands of biopharmaceutical manufacturing.

Segments:

- Cell Type: Mammalian, Non-Mammalian
- Product Type: Biologics, Biosimilars

Geographical Insights: North America Leads, Asia-Pacific Surges Ahead

North America was the largest region in the biologics CDMO market in 2023. However, Asia-Pacific is projected to be the fastest-growing region during the forecast period. This growth is driven by increasing investments in biomanufacturing infrastructure and a favorable regulatory environment. The report covers detailed insights into regional dynamics, market trends, and growth opportunities.

Access the complete report for an in-depth analysis of the global biologics CDMO market:

<https://www.thebusinessresearchcompany.com/report/biologics-cdm-global-market-report>

[Biologics CDMO Global Market](#) Report 2024 from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Biologics CDMO Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on biologics CDMO market size, biologics CDMO market drivers and trends, biologics CDMO market major players, competitors' revenues, market positioning, and market growth across geographies. The biologics CDMO market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:
[Biodegradable Plastics Global Market Report 2024](#)

<https://www.thebusinessresearchcompany.com/report/biodegradable-plastics-global-market-report>

Soap And Other Detergents Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/soap-and-other-detergents-global-market-report>

Detergent Chemicals Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/detergent-chemicals-global-market-report>

About The Business Research Company

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/721762561>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

